Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
250.00    0.00 (0.00%)
Bid:
245.00
Ask:
255.00
Spread: 10.00 (4.082%)
Market Cap: £227.11m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Board Changes

12 May 2021 09:00

RNS Number : 2860Y
Concurrent Technologies PLC
12 May 2021
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain

 

12 May 2021

 

Concurrent Technologies Plc

 

Board Changes

 

Concurrent Technologies Plc (AIM: CNC), a world leading specialist in the design and manufacture of high-performance embedded computer boards for critical applications, is pleased to announce the appointment of Dr Miles Adcock as Chief Executive Officer and as an executive director of the Company with effect from 21 June 2021.

 

The Company also announces today that Jane Annear, Managing Director, has given notice of her retirement after 36 years of outstanding service to the Company. Jane will work to support Miles in her remaining time with the Company in order to ensure an orderly transition and will continue as an executive director of the Company during that time.

 

Dr Miles Adcock is currently President of Space Imaging at Teledyne Technologies Inc. Prior to joining Teledyne, Miles held senior roles at QinetiQ Group plc including as Managing Director of its Cyber, Information & Training business unit and as Group Engineering Director. He has previously worked at BAE Systems and GEC Marconi. A Chartered Engineer and a Chartered Physicist, he received his PhD in Adaptive Optics from Imperial College, London.

 

Mark Cubitt, Non-executive Chairman of Concurrent Technologies, commented:

 

"We are delighted to welcome Miles as Chief Executive Officer of Concurrent Technologies. His experience in growing international based technology companies will help drive forward the Company to take the next steps in our development as a leading player in the high performance embedded market. It is also important we recognise today the significant role Jane has played in the growth of the Company, which she has served since she joined as our second employee on incorporation in 1985."

 

Dr Miles Adcock commented:

 

"I am very pleased to take up this role. Concurrent Technologies is a fantastic organisation. We have great people and technological capabilities and a competitive customer offering. I look forward to leading Concurrent Technologies in its next phase of growth and creating value for all our stakeholders."

 

Jane Annear, Managing Director, commented:

 "It has been a privilege to lead the team at Concurrent Technologies for the last 2 years and I would like to thank all of our employees for their commitment and support during that time. I am pleased to welcome Miles to the role of Chief Executive Officer in a new and exciting era for the Company."

 

 

 

 

Enquiries:

 

Concurrent Technologies PlcJane Annear, Managing Director

 

+44 (0)1206 752626

Newgate (Financial PR)Bob Huxford

Isabelle Smurfit

 

+44 (0)20 7653 9848+44 (0)20 3757 3411

Cenkos Securities Plc (NOMAD)Neil McDonald

Peter Lynch

+44 (0)131 220 9771

+44 (0)131 220 9772

 

The following information regarding the appointment of Dr Miles Adcock (aged 48) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

Full Name:

Miles John Adcock

 

Current Directorship / Partnerships:

South East LEP Limited

Teledyne e2v Ltd

Teledyne UK Limited

 

Previous Directorship / Partnerships:

BJ Trustee Limited

Bolden James Limited

Cuesim Limited

Gyldan 11 Limited

Leading Technology Limited

Qinetiq Special Project Inc.

 

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

 

Note to Editors:

 

About Concurrent Technologies Plc

 

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high performance, long life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest 9th generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom® processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

 

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

 

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAKSFFFLFEFA
Date   Source Headline
27th Dec 20137:00 amRNSTrading Update
13th Dec 20134:31 pmRNSProduct Launch
6th Dec 20131:35 pmRNSHolding(s) in Company
28th Nov 201311:31 amRNSHolding(s) in Company
1st Nov 20133:45 pmRNSTotal Voting Rights
24th Oct 20134:13 pmRNSProduct Launch
23rd Oct 20132:56 pmRNSTransaction in Own Shares
8th Oct 20132:35 pmRNSProduct Launch
4th Oct 20135:01 pmRNSTransaction in Own Shares
1st Oct 20133:13 pmRNSTotal Voting Rights
25th Sep 20132:38 pmRNSTransaction in Own Shares
4th Sep 20132:42 pmRNSTransaction in Own Shares
22nd Aug 20137:00 amRNSInterim Results
16th Aug 20133:58 pmRNSNotice of Results
12th Aug 201312:40 pmRNSTrading Update
21st Jun 201312:20 pmRNSHolding(s) in Company
4th Jun 20137:00 amRNSProduct Launch
28th May 20132:00 pmRNSAGM Statement
24th May 20133:10 pmRNSProduct Launch
13th May 20134:25 pmRNSProduct Launch
24th Apr 20135:01 pmRNSDistribution of Annual Report and Accounts
9th Apr 20137:00 amRNSFinal Results
19th Mar 20134:25 pmRNSNotice of Results & Dividend
1st Mar 20132:15 pmRNSProduct Launch
24th Dec 20127:00 amRNSTrading Update
21st Dec 20121:17 pmRNSProduct Launch
21st Nov 20123:27 pmRNSHolding(s) in Company
5th Nov 201212:25 pmRNSProduct Launch
31st Oct 201210:32 amRNSTotal Voting Rights
19th Sep 20125:28 pmRNSHolding(s) in Company
5th Sep 20127:00 amRNSInterim Results
29th Aug 20125:36 pmRNSNotice of Results
22nd Jun 20124:42 pmRNSTotal Voting Rights
14th Jun 20123:50 pmRNSTransaction in Own Shares
7th Jun 20127:00 amRNSProduct Launch
31st May 20123:30 pmRNSTotal Voting Rights
29th May 20121:30 pmRNSAGM Statement
22nd May 201212:21 pmRNSTreasury Shares
8th May 20127:00 amRNSDistribution of Annual Report and Accounts
4th May 20123:53 pmRNSHolding(s) in Company
17th Apr 20123:51 pmRNSHolding(s) in Company
12th Apr 201211:44 amRNSHolding(s) in Company
26th Mar 20127:00 amRNSPreliminary Results
16th Mar 20123:17 pmRNSNotice of Results
6th Mar 20121:45 pmRNSDividend Declaration
16th Jan 20127:00 amRNSProduct Launch
29th Dec 20115:46 pmRNSDirector/PDMR Shareholding
22nd Dec 201112:41 pmRNSTrading Statement
9th Dec 20114:53 pmRNSProduct Launch
2nd Dec 201111:03 amRNSProduct Launch

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.